A Vaccine Trial for Low Grade Gliomas

Launched by JAMES FELKER · Feb 5, 2015

Keywords

ClinConnect Summary

This clinical trial is studying a new vaccine designed to help children with low-grade gliomas, which are slow-growing brain tumors that cannot be surgically removed. The vaccine aims to boost the immune system's ability to fight the tumor and will be tested in young patients who have already tried at least two other treatments, such as chemotherapy. To be eligible, children must be between 12 months and 22 years old, have a specific blood marker (HLA-A2 positive), and be in stable health without serious infections.

Participants in this trial can expect to receive the vaccine along with other treatments while being closely monitored for safety and effectiveness. It's important to know that this study is currently looking for participants in North America and has specific health criteria to ensure the safety of everyone involved. If you think your child might be eligible, this could be an opportunity to access a new treatment option while contributing to important research in cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Tumor Type
• • Unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiation therapy counts as a biologic regimen. Patients may not have received radiation therapy to the index lesion within 1 year of enrollment. Patients may have tumor spread within the central nervous system (CNS).
• • HLA-A2 positive based on flow cytometry.
• • Patients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day, max 4 mg/day Dexamethasone) corticosteroid for at least one week prior to study registration.
• • Patients must be ≥ 12 months and \< 22 years of age at the time of HLA-A2 screening.
• • Patients must have a performance status of ≥ 70; (Karnofsky if \> 16 years and Lansky if ≤ 16 years of age.
• • Documented negative serum beta-human chorionic gonadotropin (HCG) for female patients who are post-menarchal. Because the effect of the peptide-based vaccine and poly-ICLC on the fetus has not sufficiently been investigated, pregnant females will not be included in the study.
• • Patients must be free of systemic infection requiring IV antibiotics at the time of registration. Patients must be off IV antibiotics for at least 7 days prior to registration.
• • Patients with adequate organ function as measured by: Bone marrow: absolute neutrophil count (ANC) \> 1,000/µ; Platelets \> 100,000/µ (transfusion independent); absolute lymphocyte count of ≥ 500/µ; Hemoglobin \>8 g/dl (may be transfused). Hepatic: bilirubin \< 1.5x institutional normal for age; serum glutamate pyruvate transaminase (SGPT) \< 3x institutional normal.
• • Renal: Serum creatinine based on age or Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 ml/min/ml/min/1.73 m²
• • Patients must have recovered from the toxic effects of prior therapy to grade 1 or better. Patients must be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy.
• • No overt cardiac, gastrointestinal, pulmonary or psychiatric disease.
• Exclusion Criteria:
• • Patients living outside of North America are not eligible.
• • Patients may not have received radiation to the index lesion within 1 year of enrollment.
• * Concurrent treatment or medications (must be off for at least 1 week) including:
• • Interferon (e.g. Intron-A®)
• • Allergy desensitization injections
• • Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)
• • Interleukins (e.g. Proleukin®)
• • Any investigational therapeutic medication
• • Patients must not have a history of, or currently active autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement.
• • Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents. Dexamethasone, or other corticosteroid medications, if used in the peri-operative period must be tapered to no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration. Topical corticosteroids are acceptable.
• • Because patients with immune deficiency are not expected to respond to this therapy, HIV-positive patients are excluded from the study.
• • Patients who have received prior immunotherapy.